Vertex Pharmaceuticals Incorporated (FRA:VX1)
Germany
· Delayed Price · Currency is EUR 381.05
-1.40 (-0.37%)
Last updated: Jun 26, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B USD in the quarter ending March 31, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to $11.10B, up 8.98% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.10B
Revenue Growth
+8.98%
P/S Ratio
9.48
Revenue / Employee
$1.82M
Employees
6,100
Market Cap
97.33B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.15B |
| Siemens Aktiengesellschaft | 77.82B |
| Deutsche Telekom AG | 120.25B |
| Allianz SE | 109.03B |
| Rheinmetall AG | 10.48B |
| Siemens Energy AG | 37.44B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
| Siemens Healthineers AG | 23.14B |
Vertex Pharmaceuticals News
- 21 hours ago - Vertex Pharmaceuticals Unusual Options Activity - Benzinga
- 1 day ago - Revenues at cystic fibrosis drugmaker Vertex hit $2.63bn on back of Kaftrio sales - Independent Ireland
- 4 days ago - Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Benzinga
- 4 days ago - Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Business Wire
- 4 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript - Seeking Alpha
- 6 days ago - Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions - Business Wire
- 16 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga